Mifepristone and first trimester abortion

Clinical Obstetrics and Gynecology

Volumn 39, Issue 2, 1996, Pages 474-485

  Murray, Shona ^a   Muse, Ken ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMEPROST; MIFEPRISTONE; MISOPROSTOL;

ANOREXIA; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG SAFETY; FIRST TRIMESTER PREGNANCY; GASTROINTESTINAL TOXICITY; HEADACHE; HORMONAL REGULATION; HORMONE INHIBITION; HUMAN; INDUCED ABORTION; INTRAVAGINAL DRUG ADMINISTRATION; LABOR INDUCTION; MASTALGIA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; REVIEW; VERTIGO;

ABORTIFACIENT AGENTS; ABORTION, DRUG INDUCED; ABORTION, INDUCED; BIOLOGY; CONTRACEPTION; CONTRACEPTIVE AGENTS; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE AGENTS, POSTCOITAL; ENDOCRINE SYSTEM; FAMILY PLANNING; FERTILITY CONTROL, POSTCONCEPTION; HEALTH; HORMONE ANTAGONISTS; HORMONES; LITERATURE REVIEW; PHYSIOLOGY; REPRODUCTIVE HEALTH--WOMEN; RU-486--ADMINISTRACTION AND DOSAGE; RU-486--CONTRAINDICATIONS;

ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, INDUCED; ADOLESCENT; DEVELOPING COUNTRIES; FEMALE; HUMANS; MIFEPRISTONE; PATIENT ACCEPTANCE OF HEALTH CARE; PREGNANCY; PREGNANCY IN ADOLESCENCE; PREGNANCY TRIMESTER, FIRST; UNITED STATES;

EID: 0030012804     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-199606000-00021     Document Type: Review

References (59)

1. Abortion and quality of care. International Planned Parenthood Federation Annual Report. New York, 1991-1992.
2. Mahler H. The safe motherhood initiative: a call to action! Lancet. 1987:1;668.
3. Philibert D, Deraedt R, Teutsch G. RU 486: a potent antiglucocorticoid in vivo. Tokyo, Japan: The 8th International Congress of Pharmacology, Abstract. 1463.
4. Baulieu EE. Fertility control in women: results with RU 486 by the end of 1985. J Steroid Biochem. 1986:25;847-851.
5. Johannisson E, Oberholzer M, Swahn ML, Bygdeman M. Vascular changes in the human endometrium following the administration of the progesterone antagonist RU 486. Contraception. 1989:39;103-117.
6. Swahn ML, Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br J Obstet Gynaecol. 1988: 95;126-134.
7. Radestad A, Bygdeman M, Green K. Induced cervical ripening with mifepristone (RU 486) and bioconversion of arachidonic acid in human pregnant uterine cervix in the first trimester. A double-blind, randomized biomechanical and biochemical study. Contraception. 1990:41;283-292.
8. Herrman W. Wyss R, Riondel A, Philibert D, Teutsch G, Sakiz E, Baulieu EE. Effect d'un steroide anti-progesterone chez la femme: interruption dy cucle menstruel et de la grossese au bedut. C R Acad Sci Paris. 1982:294;933-938.
9. Boland R. RU 486 in France and England: corporate ethics and compulsory licensing. Law, Medicine & Health Care. 1992: 20;226-34.
10. Ulman A, Silvestre L. RU 486: the French experience. Human Reproduction. 1994: 9;126-130.
11. Grimes DA, Mishell DR Jr, David HP. A randomized clinical trial of mifepristone (RU 486) for induction of delayed menses: efficacy and acceptability. Contraception. 1992:46;1-10.
12. Van Look PFA, Bygdeman M. Antiprogestational steroids: a new dimension in human fertility regulation. In: Milligan SR, ed. Oxford Review of Reproductive Biology, Vol 11. Oxford; Oxford University Press: 1-60.
13. Karim SMM, Filshie GM. Therapeutic abortion using prostaglandin F2. Lancet. 1970:1;157-159.
14. Cameron IT, Michie AF, Baird DT. Therapeutic abortion in early pregnancy with antiprogestogen RU 486 alone or in combination with a prostaglandin analogue (Gemeprost). Contraception. 1986;34:459-468.
15. Bygdeman M, Swahn ML. Progesterone receptor blockage: effect on uterine contractility and early pregnancy. Contraception. 1985:32;45-51.
16. Thong KJ, Baird DT. Induction of abortion with mifepristone and misoprostol in early pregnancy. Br J Obstet Gynaecol. 1992: 99;1004-1007.
17. Castadot RG. Pregnancy termination: techniques, risks and complications and their management. Fertil Steril. 1986;45:5-17.
18. Ulmann A, Silvestre L, Chemama L, Rezvani Y, Renault M, Aguillaume C, Baulieu E. Medical termination of early pregnancy with mifepristone followed by a prostaglandin analogue: study in 16,369 women. Acta Obstet Gynecol Scand. 1992;71:278-283.
19. Peyron R, Aubeny E, Targosz V, Silvestre L, Renault M, Elkik R, Leclerc P, Ulmann A, Baulieu EE. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med. 1993;328:1509-1513.
20. Peplow PV. RU 486 combined with PGE1 analog in voluntary termination of early pregnancy - a comparison of recent findings with gemeprost or misoprostol. Contraception. 1994:50;69-75.
21. Collins PW. Misoprostol: discovery, development, and clinical applications. Med Res Rev. 1990;10:149-172.
22. Baird DT. Medical abortion in Britain. Br J Obstet Gynaecol. 1994:101;367-368.
23. El-Refaey H, Templeton A. Induction of abortion in the second trimester by a combination of misopristol and mifepristone: a randomized comparison between two misopristol regimens. Human Reprod. 1995: 10;475-478.
24. Puri CP, Look PFA. Newly developed competitive progesterone antagonists for fertility control. Frontiers of Hormone Research. 1991:19;126-167.
25. Norman JE, Thong KJ, Rodger MW, Baird DT. Medical abortion in women of < 56 days amenorrheoea: a comparison between gemeprost (a PGE1 analogue) alone and mifepristone and gemeprost. Br J Obstet Gynaecol. 1992;99:601-606.
26. World Health Organization Task Force. Early pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone. Fertil Steril. 1991;56: 32-40.
27. Anonymous. A death associated with mifepristone/sulprostone. Lancet. 1991: 337;969-970.
28. Zheng SR. RU 486 (mifepristone): Clinical trials in China. Acta Obstet Gynecol Scand. 1989;149 (suppl):19-23.
29. Somell C, Olund A. Induction of abortion in early pregnancy with mifepristone in conjunction with gemeprost. Acta Obstet Gynecol Scand. 1993:72;39-42.
30. Rodger MW, Baird DT. Blood loss following induction of early abortion using mifepristone (RU 486) and a prostaglandin analogue (Gemeprost). Contraception. 1989: 40;439-47.
31. Chan YF, Ho PC, Ma HK. Blood loss in termination of early pregnancy by vacuum aspiration and by combination of mifepristone and gemeprost. Contraception. 1993: 47:85-95.
32. Tang GWK, Lau OWK, Yip P. Further acceptability evaluation of RU 486 and ONO 802 as abortifacient agents in a Chinese population. Contraception. 1993:48;267-276.
33. Rodger MW, Logan AF, Baird DT. Induction of early abortion with mifepristone (RU 486) and two different doses of prostaglandin pessary (Gemeprost). Contraception. 1989;39:497-502.
34. Thonneau P, Fougeyrollas B, Spira A. Analysis of 369 abortions conducted by mifepristone (RU 486) associated with sulprostone in a French family planning center. Fertil Steril. 1994:61;627-631.
35. Fonesca W, Alencar AJC, Mota FBS, Coelho HLL. Misoprostol and congenital malformations. Lancet. 1991;338:56.
36. Lim BH, Lees DAR, Bjornsonn S, Lunan CB, Cohn MR, Stewart P, Davey A. Normal development after exposure to mifepristone in early pregnancy. Lancet. 1990;2:257-258.
37. Grimes D, Mishell DR, David HP. A randomized clinical trial of mifepristone (RU 486) for induction of delayed menses: efficacy and acceptability. Contraception. 1992;46:1-10.
38. Bates A, Pinto A, Evans J. Termination of a molar pregnancy using mifepristone and gemeprost. Br J Gynaecol. 1994:101;637-638.
39. El-Refaey, Hinshaw K, Henshaw R, Smith N, Templeton A. Medical management of missed abortion and anembryonic pregnancy. BMJ. 1992;302:1399.
40. Henshaw RC, Smith AP, Asmith NC, Murray GI. Multiple fetal anomalies in the first trimester; detection using transvaginal ultrasound and therapeutic abortion using mifepristone (RU 486) in conjunction with gemeprost vaginal pessaries. Br J Obstet Gynaecol. 1992;99:258-264.
41. Radestad A, Christensen NJ, Stromberg L. Induced cervical ripening with mifepristone in first trimester abortion: a double-blind randomized biochemical study. Contraception. 1988:38;301-312.
42. Gupta JK, Johnson N. Should we use prostaglandins, tent or progesterone antagonists for cervical ripening before first trimester abortion? Contraception. 1992:46;489-497.
43. Rodger MW, Baird DT. Pretreatment with mifepristone (RU 486) reduces prostaglandin abortion interval in mid trimester therapeutic abortion. Br J Obstet Gynaecol. 1990;97:51-55.
44. Bachelt A, Cludy L, Spira A. Conditions for choosing between drug-induced and surgical abortion. Contraception. 1992;45:547-559.
45. Cameron JT, Baird DT. Early pregnancy termination: a comparison between vacuum aspiration and medical abortion using prostaglandin (16,16 dimethyl-trans-2-PGE, methyl ester) or the Antiprogestogen RU 486. Br J Obstet Gynaecol. 1988:95;271-276.
46. Rosen A, Nystedt L, Bygedeman M, Lundstrom V. Acceptability of a nonsurgical method to terminate very early pregnancy in comparison to vacuum aspiration. Contraception. 1979;10:107-117.
47. Thong KJ, Dewar MH, Baird DT. What do women want during medical abortion? Contraception. 1992;46:435-442.
48. Holmgran K. Women's evaluation of three early abortion methods. Acta Obstet Gynecol Scand. 1992;71:616-623.
49. Kaltreider NB, Goldsmith S, Margolis AJ. The impact of midtrimester abortion techniques on patients and staff. Am J Obstet Gynecol. 1979;135:235-238.
50. Henshaw R, Naji S, Russell I, Templeton A. Psychological responses following medical abortion (using mifepristone and gemeprost) and surgical vacuum aspiration. Acta Obstet Gynecol Scand. 1994;73:812-818.
51. Castel M, Coeytaux F. RU 486: Beyond the controversy: implications for health care practice. JAMA. 1994;49:156-164.
52. Creinin M, Darney P. Methotrexate and misoprostol for early abortion. Contraception. 1993;48:339-348.
53. Hausknecht RU. Methotrexate and misoprostol to terminate early pregnancy. N Engl J Med. 1995;333:537-540.
54. Zabin LS, Clarke Jr. Institutional factors affecting teenagers' choice and reasons for delay in attending a family planning clinic. Fam Plan Persp. 1983:20;4-12.
55. Henshaw SK, Van Voort J. Teenage abortion, birth and pregnancy statistics: an update. Fam Plan Pers. 1989;21:85-88.
56. Zabin LS, Hirsch MB, Boscia JA. Differential characteristics of adolescent pregnancy test patients: abortion, childbearing and negative test groups. J Adol Health Care. 1990:2;107-113.
57. Cates W. Adolescent abortions in the United States. J Adol Health Care. 1980:1;18-25.
58. Cates W, Schulz KF, Grimes DA. The risks associated with teenage abortion. N Engl J Med. 1983;309:621-624.
59. Baulieu EE. RU 486 a compound that gets itself talked about. Human Reproduction. 1994;9:1-6.